Please assess the completion status of the following clinical trial:

Trial Title: Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Documented chronic HCV GT1 infection (with no evidence of non-typable or mixed genotype)~* Absence of cirrhosis, or cirrhosis with these criteria: METAVIR F4, or Fibroscan with result \>12.5 kPa, or FibroSure® (Fibrotest®) score of \>0.75 + aspartate aminotransferase (AST): platelet ratio index (APRI) of \>2- Prior regimen containing an approved DAA (boceprevir, telaprevir, simeprevir, or sofosbuvir), pegylated interferon, and/or RBV~* Participants of reproductive potential must agree to remain truly abstinent or use (or have their partner use) 2 acceptable methods of birth control from at least 2 weeks prior to Day 1 and continue until at least 6 months after last dose of study drug, or longer if dictated by local regulations~Exclusion criteria:~* Received any HCV regimen containing a DAA with the exception of boceprevir, telaprevir, simeprevir, or sofosbuvir in combination with pegylated interferon and/or RBV~* Evidence of decompensated liver disease or cirrhosis~* Co-infected with hepatitis B virus or human immunodeficiency virus (HIV)~* History of malignancy \<=5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer or carcinoma in situ; or under evaluation for other active or suspected malignancy~* Evidence of hepatocellular carcinoma (HCC) or under evaluation for HCC~* Currently participating or has participated in a study with an investigational compound within 30 days of signing informed consent and is not willing to refrain from participating in another such study during the course of this study~* Clinically-relevant drug or alcohol abuse within 12 months of screening~* Pregnant, breast-feeding, or expecting to conceive or donate eggs or sperm from at least 2 weeks prior to Day 1 and continue throughout treatment and follow up, or longer if dictated by local regulations~* Male participant whose female partner (s) is/are pregnant~* Organ transplants (including hematopoietic stem cell transplants) other than cornea and hair~* Poor venous access~* History of gastric surgery (e.g., stapling, bypass) or history of malabsorption disorders (e.g., celiac sprue disease)~* Hemoglobinopathy, including, but not limited to, thalassemia major~* Any medical condition requiring, or likely to require, chronic systemic administration of corticosteroids during the course of the trial~* Evidence or history of chronic hepatitis not caused by HCV, including but not limited to nonalcoholic steatohepatitis (NASH), drug-induced hepatitis, and autoimmune hepatitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GZR 100 mg + EBR 50 mg + RBV for 12 weeks (Type: EXPERIMENTAL): Participants receive grazoprevir 100 mg once per day (QD), elbasvir 50 mg QD, and RBV 800 - 1400 mg total daily dose divided twice per day (based on body weight) for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete